ADVERTISEMENT

Aurobindo Pharma Q2 Results Review - U.S. Drags Down Overall Performance; Outlook Cautious: ICICI Direct

U.S. price erosion continues. U.S. injectable and ex-injectable business have de-grown by 28% YoY and 15% YoY.

<div class="paragraphs"><p>Aurobindo Pharma Ltd.’s manufacturing facility. (Source: Company website).</p></div>
Aurobindo Pharma Ltd.’s manufacturing facility. (Source: Company website).
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More